title: [Intra-arterial cisplatin and sequential radiotherapy. Long-term follow-up].
abstract: BACKGROUND
  The objective of this study was to improve the results of irradiation by prior application of intraarterial (i.a.) chemotherapy with cisplatin.
  
  
  METHODS
  Sixty-three patients suffering from advanced head and neck cancer without previous treatment were prepared for intraarterial chemotherapy by neck dissection without resection of the primary tumor and by modification of the carotid artery by creating a more inferiorly positioned bifurcation to facilitate intermittent i.a. infusion. The patients received approximately 400 mg cisplatin over a period of four to five weeks followed by irradiation with 60Co (64 Gy HD).
  
  
  RESULTS
  The survival rate at five years in all patients with adequate i.a. chemotherapy was 19 of 49 (39%), except those with adenoid-cystic carcinoma, who had a five-year-survival rate of 100%.
  
  
  CONCLUSIONS
  The results indicate that inductive i.a. chemotherapy with cisplatin has a positive influence on the outcome of irradiation even in inoperable head and neck cancer, which is defined by a longer period of remission with the possibility of curing the disease.
authors.affiliation: HNO-Abteilung, Allgemeines Krankenhaus Altona, Hamburg.
authors.forename: J V
authors.initials: JV
authors.lastname: Scheel
authors.forename: V
authors.initials: V
authors.lastname: Schilling
authors.forename: E
authors.initials: E
authors.lastname: Kastenbauer
authors.forename: D
authors.initials: D
authors.lastname: Knöbber
authors.forename: W
authors.initials: W
authors.lastname: Böhringer
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003037:Cobalt Radioisotopes / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D007261:Infusions, Intra-Arterial; D010039:Otorhinolaryngologic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage*; D011867:Radioisotope Teletherapy; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D003037:Cobalt Radioisotopes; D011838:Radiation-Sensitizing Agents; D002945:Cisplatin